This phase I trial studies the side effects and best dose of flotetuzumab and how well it works in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Immunotherapy with flotetuzumab may induce changes in the body's immune system and may interfere with the ability of leukemia cells to grow and spread. Giving flotetuzumab may stop the leukemia from growing or shrink for a period of time, as well as possibly lessening symptoms, such as pain, that are caused by the leukemia.

View full study on ClinicalTrials.gov